Suppr超能文献

诱导分娩前宫颈成熟技术的比较。

Preinduction cervical ripening techniques compared.

作者信息

Greybush M, Singleton C, Atlas R O, Balducci J, Rust O A

机构信息

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Hospital, 17th and Chew Streets, P.O. Box 7017, Allentown, PA 18105-7017, USA.

出版信息

J Reprod Med. 2001 Jan;46(1):11-7.

Abstract

OBJECTIVE

To assess the clinical efficacy of pharmacologic, mechanical and combination techniques of cervical ripening.

STUDY DESIGN

From March 1997 to August 1998, all cervical-ripening patients at Lehigh Valley Hospital were randomly assigned to three groups: intravaginal misoprostol, intracervical Foley catheter, or combination prostaglandin E2 (PGE2) gel and Foley catheter. Inclusion criteria included Bishop score < or = 5 and no contraindication to labor. The remaining delivery process was actively managed according to established guidelines. Multiple variables in perinatal outcome were analyzed, with the cesarean section rate and time from ripening to delivery as the main outcome variables.

RESULTS

Of the 205 patients, 65 were randomized to the misoprostol group, 71 to the Foley group and 69 to the catheter-and-gel group. There were no differences between groups in delivery indications, maternal demographics, ultrasound findings, labor interventions, intrapartum times, mode of delivery, postpartum complications or neonatal outcomes. The misoprostol group demonstrated a higher rate of uterine tachysystole and required oxytocin less when compared to the two catheter groups.

CONCLUSION

The higher rate of uterine tachysystole with misoprostol did not increase the cesarean section rate. The higher rate of oxytocin required by the two catheter groups did not increase the delivery time intervals. There appears to be no benefit to adding intracervical or intravaginal PGE2 gel to the intracervical Foley balloon. The misoprostol and catheter ripening techniques have similar safety and efficacy.

摘要

目的

评估宫颈成熟的药物、机械及联合技术的临床疗效。

研究设计

1997年3月至1998年8月,利哈伊谷医院所有宫颈成熟患者被随机分为三组:阴道内使用米索前列醇组、宫颈内放置福莱氏尿管组或联合使用前列腺素E2(PGE2)凝胶与福莱氏尿管组。纳入标准包括 Bishop 评分≤5 且无引产禁忌证。其余分娩过程按照既定指南进行积极管理。分析围产期结局的多个变量,以剖宫产率和从宫颈成熟到分娩的时间作为主要结局变量。

结果

205例患者中,65例随机分配至米索前列醇组,71例至福莱氏尿管组,69例至尿管加凝胶组。各组在分娩指征、产妇人口统计学特征、超声检查结果、分娩干预措施、产时时间、分娩方式、产后并发症或新生儿结局方面均无差异。与两个尿管组相比,米索前列醇组子宫收缩过速发生率较高,且催产素使用需求较少。

结论

米索前列醇导致的较高子宫收缩过速发生率并未增加剖宫产率。两个尿管组较高的催产素使用需求并未增加分娩时间间隔。在宫颈内福莱氏球囊基础上加用宫颈内或阴道内PGE2凝胶似乎并无益处。米索前列醇和尿管成熟技术具有相似的安全性和疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验